WSB1 Inhibitors
Chemical inhibitors of WSB1 can affect the protein's function through various biochemical pathways. For example, ML-7 can indirectly inhibit WSB1 by targeting myosin light chain kinase (MLCK), which is essential for cytoskeleton dynamics that WSB1 is known to be involved with, particularly relating to proteasomal degradation. Similarly, PD98059 and U0126, both MEK1/2 inhibitors, can disrupt the ERK1/2 signaling pathway, which has implications for WSB1's role in the ubiquitination process. By inhibiting MEK1/2, these chemicals can decrease the phosphorylation and activation of ERK1/2, thereby dampening the downstream effects that influence WSB1 activity.
Additionally, PI3K inhibitors such as LY294002 and Wortmannin can indirectly inhibit WSB1 through the attenuation of Akt signaling. Given that WSB1 is implicated in regulating components of the PI3K/Akt pathway, disruption of this signaling can impede WSB1's function in protein degradation. Proteasome inhibitors like Bortezomib, MG132, and Lactacystin also indirectly inhibit WSB1, but through a different mechanism. These chemicals prevent the degradation of proteins that WSB1 targets for ubiquitination, thereby reducing WSB1's role in the proteasomal degradation pathway. Moreover, SB203580, a p38 MAPK inhibitor, can hinder WSB1's stress response activities, as p38 MAPK is involved in stress signaling pathways where WSB1 plays a regulatory role. Similarly, SP600125 inhibits JNK, which is part of regulatory processes involving WSB1, particularly in the stress response and ubiquitin-proteasome pathway. Lastly, Rapamycin's inhibition of mTOR can lead to reduced activity of protein synthesis and degradation processes, thereby affecting WSB1's functional role in these areas.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
As an inhibitor of myosin light chain kinase (MLCK), ML-7 can indirectly inhibit WSB1 by preventing the phosphorylation of myosin II, which is critical for cytoskeleton dynamics. Since WSB1 is involved in regulating proteasomal degradation related to cytoskeletal proteins, altering cytoskeleton dynamics can impede WSB1's ability to interact with its targets. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits the MEK1/2 pathway, which is upstream of ERK1/2 signaling. WSB1 has been linked to the ubiquitin-proteasome system and may be influenced by changes in ERK1/2 activity. By inhibiting this pathway, PD98059 can reduce the activity of ERK1/2, potentially leading to the decreased functional activity of WSB1 in the ubiquitination process. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and by inhibiting PI3K, it can attenuate Akt signaling. As WSB1 is suggested to be involved in regulating components in the PI3K/Akt pathway, inhibition of this pathway by LY294002 can indirectly inhibit WSB1's function by disrupting the cellular processes that WSB1 is known to influence, particularly in protein degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can indirectly inhibit WSB1 by preventing the degradation of proteins WSB1 would typically target for ubiquitination and subsequent degradation. By inhibiting the proteasome, WSB1's role in targeting proteins for degradation is undermined, thus functionally inhibiting WSB1's activity in the cell. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. Since WSB1 has been implicated in stress response signaling pathways, which are regulated by p38 MAPK, inhibiting p38 MAPK can impede the stress-induced activities of WSB1, particularly its role in proteasomal degradation under stress conditions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which participates in regulatory processes that can involve WSB1. By inhibiting JNK, SP600125 can disrupt these regulatory processes, thus indirectly inhibiting WSB1's function related to the stress response and ubiquitin-proteasome pathway. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 functions as a proteasome inhibitor, similar to Bortezomib. It can indirectly inhibit WSB1 by blocking the proteasomal degradation pathway, thus preventing WSB1 from fulfilling its role in tagging proteins for degradation. This inhibition can functionally disrupt the turnover of proteins that WSB1 is associated with in cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, similar to PD98059, and serves to block ERK1/2 signaling. Since WSB1 can be connected to signaling pathways that involve ERK, inhibition of MEK1/2, and by extension ERK1/2, by U0126 can result in a functional inhibition of WSB1's activity, particularly in its regulatory roles related to protein degradation and cellular stress responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that, like LY294002, can impede the PI3K/Akt pathway. By doing so, it can indirectly inhibit WSB1 by disrupting the signaling pathways that WSB1 is implicated in, particularly those involved in proteasomal degradation and cell survival, thereby affecting WSB1's functional role in these processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Inhibition of mTOR can lead to reduced activity of cellular processes that are crucial for protein synthesis and degradation, both of which are processes WSB1 has a role in. By functionally inhibiting mTOR, rapamycin can indirectly inhibit WSB1 by altering the environment in which WSB1 operates, particularly affecting protein turnover. | ||||||